Metabolic Syndrome Epidemiology and Management

Metabolic syndrome, defined by a constellation of central obesity, dyslipidaemia, hypertension and hyperglycaemia, affects an estimated one quarter to one third of adults worldwide and represents a major driver of cardiovascular disease and type 2 diabetes. Prevalence varies substantially by region, age, sex and socioeconomic status, with urbanisation and ageing populations fuelling a steady rise in many countries. Underlying pathophysiology centres on insulin resistance and adipose tissue inflammation, which precipitate atherogenic lipid profiles, elevated blood pressure and impaired glucose regulation. Public health efforts have focused on primary prevention through lifestyle interventions promoting weight loss, balanced diets and increased physical activity, while clinical management strategies integrate pharmacological control of individual components alongside personalised risk stratification. Emerging approaches emphasise early detection using continuous severity metrics, demographic-specific thresholds and biomarker panels, allowing tailored interventions and improved resource allocation. Multidisciplinary care pathways and policy initiatives targeting obesogenic environments are critical to curb the socioeconomic burden and mitigate long-term complications.

Research from Nature Portfolio

A recent study introduced a continuous, age-, sex- and ethnicity-specific metabolic syndrome severity score based on waist circumference, triglycerides, high-density lipoprotein cholesterol, mean arterial pressure and fasting blood glucose. By assigning subgroup-specific weights to each parameter, the score achieved enhanced sensitivity for predicting future cardiovascular and metabolic complications across diverse populations, offering a refined tool for early risk stratification and preventive medicine.

Metabolic Syndrome Epidemiology and Management publication trend

The graph below shows the total number of articles in metabolic syndrome epidemiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolic syndrome: cluster of interrelated cardiovascular risk factors including central obesity, dyslipidaemia, hypertension and hyperglycaemia that predispose to type 2 diabetes and cardiovascular disease.

Waist circumference: measure of abdominal adiposity reflecting central fat distribution and associated metabolic risk.

Triglycerides: circulating lipids that when elevated indicate atherogenic dyslipidaemia and insulin resistance.

High-density lipoprotein cholesterol (HDL-C): “good” cholesterol involved in reverse lipid transport; reduced levels are a component of metabolic syndrome.

Mean arterial pressure (MAP): average arterial pressure throughout the cardiac cycle, calculated from systolic and diastolic blood pressure.

Fasting blood glucose: concentration of glucose in plasma after an overnight fast, an indicator of glycaemic control and insulin sensitivity.

MetS severity score: a continuous metric integrating weighted metabolic parameters to quantify syndrome severity across demographic subgroups.

References

1. Development and validation of an age-sex-ethnicity-specific metabolic syndrome score in the Chinese adults. Nature Communications (2023).
2. Longitudinal economic burden of incident complications among metabolic syndrome populations. Cardiovascular Diabetology (2024).
3. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health (2017).
4. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Medicine (2012).
5. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovascular Diabetology (2020).